REGN — REGENERON PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 872589 ·
Last close
$797.99
Market Cap
$80.71B
52W High
$813.63
52W Low
$591.52
ADV30
813,173
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 4,290,700,000 | 3,714,200,000 | 1,420,500,000 | 1,296,900,000 | 41,730,600,000 | 2,455,800,000 | 10,019,200,000 |
| Mar 2026 | 3,605,400,000 | 2,936,000,000 | 744,800,000 | 727,200,000 | 40,868,800,000 | 2,962,600,000 | 9,445,200,000 |
| Dec 2025 | 3,884,300,000 | 3,299,700,000 | 898,600,000 | 844,600,000 | 40,558,700,000 | 3,118,100,000 | 9,301,800,000 |
| Sep 2025 | 3,754,300,000 | 3,232,700,000 | 1,109,900,000 | 1,460,000,000 | 40,169,400,000 | 2,506,400,000 | 9,211,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,681,300,000
Investing CF
$-704,200,000
Financing CF
$-3,524,800,000
CapEx
$-1,106,100,000
Dividends Paid
$-378,500,000
Buybacks
$-3,902,400,000
EPS Diluted TTM
$40.46
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$37,621,400,000
Inventory
$3,084,300,000
Receivables
$6,565,400,000
ST Investments
$5,538,800,000
EBIT TTM
$5,221,400,000
Pretax Income TTM
$5,166,000,000
Interest Exp TTM
$55,400,000
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,534,699,520
EBITDA
$4,702,400,000
Free Cash Flow
$3,065,299,968
Enterprise Value
$74,395,279,360
Total Cash
$7,994,599,936
Total Debt
$2,706,599,936
Shares Out
101,137,842
Trailing EPS
$40.46
Book Value
$316.11
ROE
14.0%
ROA
6.5%
Div Yield
0.47%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,342,900,000 | 3,702,000,000 | 4,504,900,000 | 40,558,700,000 | 9,301,800,000 | — | 4,978,900,000 |
| Dec 2024 | 14,202,000,000 | 3,990,700,000 | 4,412,600,000 | 37,759,400,000 | 8,405,800,000 | — | 4,420,500,000 |
| Dec 2023 | 13,117,200,000 | 4,047,100,000 | 3,953,600,000 | 33,080,200,000 | 7,107,100,000 | — | 4,594,000,000 |
| Dec 2022 | 12,172,900,000 | 4,738,900,000 | 4,338,400,000 | 29,214,500,000 | 6,550,500,000 | — | 5,014,900,000 |
TTM Snapshot
Revenues TTM
$3,720,700,000
NetIncome TTM
$1,340,600,000
OpCashFlow TTM
$0
Assets (Latest)
$37,759,400,000
Forward EPS
$60.11
Max Pain — expiry 2026-08-21
max pain strike: $655.00 · spot: $805.97 · call oi: 3,196 · put oi: 3,241Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GSK | GSK plc | $100.74B | $50.30 | — |
| GLAXF | GSK plc | $103.59B | $25.86 | — |
| SNYNF | Sanofi | $104.35B | $87.10 | — |
| SNY | Sanofi | $104.74B | $43.71 | — |
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $55.60B | $17.41 | — |
News headlines (Yahoo Finance, 1h cache)
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 11:00 · Yahoo
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs
2026-08-12 11:16 · Yahoo
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
2026-08-11 14:30 · Yahoo
Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight
2026-08-08 23:11 · Yahoo
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
2026-08-07 14:46 · Yahoo
CytomX Therapeutics Q2 Earnings Call Highlights
2026-08-07 01:03 · Yahoo
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
2026-08-06 20:15 · Yahoo
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ...
2026-08-06 19:03 · Yahoo
Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock
2026-08-05 16:20 · Yahoo
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
2026-08-05 15:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.